Geoffrey R Oxnard

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
  2. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
  3. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
  4. pmc EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma
    Mai He
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:1790-7. 2012
  5. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
  6. pmc "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Christian Grommes
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1364-9. 2011
  7. pmc Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes
    Geoffrey R Oxnard
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:3114-9. 2011
  8. pmc A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
    Binsheng Zhao
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 16:4647-53. 2010
  9. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
  10. pmc Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Maria E Arcila
    Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:1169-80. 2011

Collaborators

Detail Information

Publications15

  1. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
    ..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...
  2. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
    ..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI...
  3. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
    ..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI...
  4. pmc EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma
    Mai He
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:1790-7. 2012
    ..EGFR exon 19 insertions are a poorly described family of EGFR mutations, and their association with EGFR-TKI sensitivity in lung adenocarcinoma is uncertain...
  5. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
    ..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib...
  6. pmc "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Christian Grommes
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1364-9. 2011
    ..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned...
  7. pmc Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes
    Geoffrey R Oxnard
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:3114-9. 2011
    ..In this study, we assess the variability of lung tumor measurement using repeat CT scans performed within 15 minutes of each other and discuss the implications of this variability in a clinical context...
  8. pmc A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
    Binsheng Zhao
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 16:4647-53. 2010
    ....
  9. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  10. pmc Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Maria E Arcila
    Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:1169-80. 2011
    ..Positive cases were evaluated for T790M using standard PCR-based methods and a subset were re-evaluated with an LNA-PCR/sequencing method with an analytical sensitivity of approximately 0.1%. MET amplification was assessed by FISH...
  11. ncbi request reprint Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
    Geoffrey R Oxnard
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:392-9. 2010
    ..Currently active trials are referenced using their ClinicalTrials.gov identifier...
  12. pmc Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
    Juliann Chmielecki
    Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
    Sci Transl Med 3:90ra59. 2011
    ..This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance...
  13. ncbi request reprint Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
    ....
  14. ncbi request reprint Non-small cell lung cancer in octogenarians: treatment practices and preferences
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Thorac Oncol 2:1029-35. 2007
    ..Treatment practices in this patient population are poorly described. In this report, we describe the treatment of a population of very elderly patients with NSCLC at a large teaching hospital...
  15. ncbi request reprint Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, USA
    Lung Cancer 52:141-8. 2006
    ..Application of the RECIST response criteria to mesothelioma thickness measurements yields PR and PD classifications based on smaller volume changes than for spherical tumors...